All In Biotech

Drug Trial Radar · NCT03290235

Extension Study of Pegylated Somatropin to Treat Growth Retardation Caused by Endogenous Growth Hormone Deficiency in Children

The Extension Study of Phase IV Clinical Trial of Pegylated Somatropin (PEG Somatropin) to Treat Growth Retardation Caused by Endogenous Growth Hormone Deficiency in Children

Last checked: Nov 19, 2026Latest source record: Dec 12, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

1,500

Planned (sponsor's estimate)

Start

Mar 1, 2017

Primary completion

Oct 2020

Study completion Sep 2021

Sponsor

Sponsor type
Industry
First posted
Sep 21, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 42 months, up to 15 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

1. To further evaluate the safety and efficacy of PEG-Somatropin in the treatment of children with growth hormone deficiency for a relatively long period 2. To explore the factors influencing the efficacy of PEG-Somatropin and to establish the height prediction model based on Chinese children with short stature, and to provide the basis and guidance for standard and reasonable long-term clinical application of PEG-Somatropin.

Conditions

  • Growth Retardation

Interventions

  • PEG-somatropinDrug

    Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/kit

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ht SDSca (Height standard deviation score for chronological age)Time frame: Baseline, every 13 weeks until 130 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • TongJi hospital affiliated to TongJi medical college of HuaZhong university of Science & Teconology

    Wuhan, Hubei, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.